Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Aug 10, 2012

NEW YORK (GenomeWeb News) – Dale Levitzke has been appointed vice president of global sales for life sciences at NanoString Technologies. Levitzke joins the company from Illumina, where he was senior director and global sales manager for the company's PCR division.

Previously, he was head of global sales for Helixis, general manager of Corbett Robotics, and core facility manager at the University of Newcastle's Analytical and Biomolecular Research Facility. He holds a BS in molecular biology from La Trobe University Melbourne.


Agendia said this week that Stefan Gluck will serve as chair of its medical advisory board. Gluck is a professor at the Miller School of Medicine at the University of Miami. He spent five years as clinical director of the Braman Family Breast Cancer Institute and had previously served as director of the Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center and as a professor at the University of Calgary.


Accelr8 has named Steve Reichling to be company CFO. Reichling joins Accelr8 from Roche Tissue Diagnostics, where he was GM of its Spring Bioscience antibody R&D and research products subsidiary. He also worked in finance at Ventana Medical Systems and he was a life sciences auditor at Ernst and Young.


Response Biomedical said this week that Bill Adams will take over the CFO position from Richard Canote, who has resigned that title but will remain with the company as a consultant, as of August 13. Adams previously was CFO at CellFor, and before that he held the same job at AnorMed and at Epic Data.


ILS Genomics said this week that Leslie Recio has been appointed as director of its new genomics division, where she will be responsible for the company's scientific pursuits and development, as well as identifying and integrating new technology platforms.

Recio also is division director of ILS' Genetic and Molecular Toxicology Division, and she has over 25 years of experience in toxicological research focused on mutagenesis, toxicogenomics, and regulatory-based genotoxicity assessment.


Response Genetics' stockholders have re-elected the members of its board of directors for one-year terms, including company CEO and Chairman Thomas Bologna; Kick Calhoun; Michael Metzger; Gary Nusbaum; Michael Serruya; Richard van den Broek; and David Wurzer.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.